Nuvalent(US:NUVL) Financial Modeling Prepยท2025-11-18 00:10Company Overview - Nuvalent, Inc. is a biopharmaceutical company focused on developing targeted therapies for cancer treatment, particularly its drug neladalkib for advanced ALK-positive non-small cell lung cancer (NSCLC) [1] - The company faces competition from other biotech firms working on similar cancer therapies [1] Recent Developments - On November 17, 2025, Leerink Partners set a price target of $149 for NUVL, indicating a potential upside of 34.77% from its current price of $110.56 [2][5] - The optimistic outlook is supported by promising topline results from the ALKOVE-1 Phase 1/2 trial, which showed a 31% response rate among 253 patients with advanced ALK-positive NSCLC [2][5] Clinical Trial Insights - The trial results are significant as they involve patients previously treated with tyrosine kinase inhibitors (TKIs) and chemotherapy [3] - The recommended Phase 2 dose of neladalkib is 150 mg once daily, determined during the Phase 1 dose-escalation stage, indicating potential for further clinical development in this heavily pretreated patient population [3] Stock Performance - NUVL's stock price is currently $110.11, reflecting a 14.10% increase or $13.61, with fluctuations between $93.30 and $112.52 today [4] - The company's market capitalization is approximately $8 billion, with a trading volume of 1,681,393 shares on the NASDAQ exchange [4][5]